Literature DB >> 20824008

Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.

Nadia Harbeck1, Manfred Schmitt, Martina Vetter, Janna Krol, Daniela Paepke, Mathias Uhlig, Stefan Paepke, Fritz Jänicke, Anneke Geurts-Moespot, Gunter von Minckwitz, Fred Sweep, Christoph Thomssen.   

Abstract

Entities:  

Year:  2008        PMID： 20824008      PMCID： PMC2930996          DOI： 10.1159/000151734

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  21 in total

1.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

Review 2.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

3.  Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

Authors:  F Jänicke; M Schmitt; K Ulm; W Gössner; H Graeff
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

4.  Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Authors:  Nadia Harbeck; Ronald E Kates; Manfred Schmitt
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

5.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Authors:  J A Foekens; H A Peters; M P Look; H Portengen; M Schmitt; M D Kramer; N Brünner; F Jänicke; M E Meijer-van Gelder; S C Henzen-Logmans; W L van Putten; J G Klijn
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

6.  Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.

Authors:  S J Kim; E Shiba; T Kobayashi; E Yayoi; J Furukawa; Y Takatsuka; E Shin; H Koyama; H Inaji; S Takai
Journal:  Clin Cancer Res       Date:  1998-01       Impact factor: 12.531

7.  Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.

Authors:  M J Duffy; P O'Grady; D Devaney; L O'Siorain; J J Fennelly; H J Lijnen
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

8.  Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.

Authors:  Fred C G J Sweep; Herbert A Fritsche; Massimo Gion; George G Klee; Manfred Schmitt
Journal:  Int J Oncol       Date:  2003-12       Impact factor: 5.650

Review 9.  Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Authors:  Nadia Harbeck; Ronald E Kates; Katja Gauger; Amina Willems; Marion Kiechle; Viktor Magdolen; Manfred Schmitt
Journal:  Thromb Haemost       Date:  2004-03       Impact factor: 5.249

10.  Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.

Authors:  C Bouchet; M Ferrero-Poüs; K Hacène; V Becette; F Spyratos
Journal:  Int J Biol Markers       Date:  2003 Jul-Sep       Impact factor: 3.248
View more
  3 in total

1.  Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissues.

Authors:  D S Lang; S Marwitz; U Heilenkötter; W Schumm; O Behrens; R Simon; M Reck; E Vollmer; T Goldmann
Journal:  Pathol Oncol Res       Date:  2014-03-09       Impact factor: 3.201

2.  Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.

Authors:  Elise Deluche; Laurence Venat-Bouvet; Sophie Leobon; Veronique Fermeaux; Joelle Mollard; Nadira Saidi; Isabelle Jammet; Yves Aubard; Nicole Tubiana-Mathieu
Journal:  BMC Cancer       Date:  2017-09-27       Impact factor: 4.430

3.  Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.

Authors:  Wenrui Hao; Avner Friedman
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.